Results 241 to 250 of about 58,384 (313)

Outcomes and Usability of Formoterol-Budesonide Delivered Through Synchrobreathe^® in Patients With Chronic Obstructive Pulmonary Disease: The EMERGE Study. [PDF]

Drugs Real World Outcomes
Balamurugan S, Pophale H, Samariya U, Apte K, Singh S, Dhar R, Rajan S, Swarnakar R, Talwar D, Lopez M, Naik V, Sawant S, Chhowala S, Vaidya A, Gogtay J.   +14 more
europepmc   +1 more source

Trachealisation of the Oesophagus in Lymphocytic Oesophagitis: An Uncommon Endoscopic Presentation. [PDF]

Cureus
Mohamed Maheen MA, Hameed K, Andrew MR.
europepmc   +1 more source

Treatment of Recurrent IgA Nephropathy After Kidney Transplantation: Case Report and Comprehensive Literature Review. [PDF]

Clin Case Rep
Matarneh A, Salameh O, Koirala M, Karasinski A, Kaur G, Trivedi N, Ghahramani N, Shah V.   +7 more
europepmc   +1 more source

Implementation of a stepped anti-inflammatory reliever therapy intervention with budesonide-formoterol 160/4·5 mcg by Turbuhaler versus usual care for adults presenting during exacerbations of obstructive lung disease suggestive of asthma or chronic obstructive pulmonary disease in a resource-limited setting: an open-label, cluster randomised trial. [PDF]

EClinicalMedicine
Fox GJ, Chau NQ, Yen PN, Van Giap V, Li Q, Jan S, Huang E, Negin J, Anh NT, Reddel H, Marks GB.   +10 more
europepmc   +1 more source

Exploring the molecular mechanism of budesonide enteric capsules in the treatment of IgA nephropathy based on bioinformatics. [PDF]

Sci Rep
Lin M, Chen S, Chen Y, Gao Q.
europepmc   +1 more source

Modulation of Cell Plasticity by Budesonide: Beyond the Metabolic and Anti‐Inflammatory Actions of Glucocorticoids

Eduardo J. Patriarca, Cristina D’Aniello, Dario De Cesare, Gilda Cobellis, Gabriella Minchiotti   +4 more
openalex   +2 more sources

Cost-effectiveness modeling of mortality risk reduction comparing two fixed-dose combination triple therapies in moderate-to-very severe chronic obstructive pulmonary disease. [PDF]

J Comp Eff Res
Parsekar K, Pandey S, Tansey-Dwyer D, Marshall J, Rustignoli I, Pollack M, Singh B, Ouwens M.   +7 more
europepmc   +1 more source

Steroid-sparing strategies for managing immune-related adverse events. [PDF]

J Immunother Cancer
Huang JJ, YousefiAsl M, Singh N, Grivas P, Bhatia S.   +4 more
europepmc   +1 more source

CD74-Targeting Antibody-Drug Conjugate Enhances Immunosuppression of Glucocorticoid in Systemic Lupus Erythematosus. [PDF]

Int J Mol Sci
Du Q, Yao S, Huang Y, Zhang J, Sonam W, Lu X, Yang J, Cheng S, Wang R, Xu J, Ma L, Liu Y, Wu G, Zhang J, Wang X, Lu W, Ling Z, Yi C, Sun B.   +18 more
europepmc   +1 more source